CLINICAL TRIALS PROFILE FOR MICONAZOLE 3 COMBINATION PACK

All Clinical Trials for MICONAZOLE 3 COMBINATION PACK

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004575 ↗	Effects of Miconazole on Blood Flow	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1	2000-02-01	This study will investigate the effect of the drug miconazole on blood vessel dilation. Miconazole stops production of EDHF, a substance that causes arteries to dilate. EDHF is produced by the cells that line blood vessels. Normal volunteers between the ages of 21 to 60 may participate in this study. Candidates will be screened for eligibility with a medical history, physical examination, electrocardiogram and routine laboratory tests. Those enrolled will be injected with miconazole to study its effects on blood vessels. Study participants will take three aspirin tablets. After administration of a local anesthetic, small tubes will be inserted through a needle into the artery and vein of the forearm. These will be used to measure blood pressure and to draw blood samples during the study. Forearm blood flow will be measured using pressure cuffs placed on the wrist and upper arm, and a strain gauge (a rubber band device) placed around the forearm. When the cuffs are inflated, blood will flow into the arm, stretching the strain gauge, and the flow measurement will be recorded. Small doses of four drugs-bradykinin, sodium nitroprusside, miconazole, and LNMMA-will be given through the arterial catheter. Bradykinin stimulates the release of EDHF and can lower blood pressure. Sodium nitroprusside causes blood vessels to dilate and is used to treat high blood pressure and heart failure. Miconazole is commonly prescribed to treat various infections, including vaginal yeast infections, jock itch and athlete's foot. In much higher doses, it is used to treat fungal infections that have spread to the lungs, brain, kidneys, or bladder. LNMMA inhibits production of nitric oxide, another substance produced by the lining cells of blood vessels. Blood flow will be measured throughout the study, which will last approximately 3 hours.
NCT00128323 ↗	A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis	Completed	British Society for Antimicrobial Chemotherapy	Phase 3	2002-11-01	In resource constrained societies and where HIV is a problem, oral thrush causes significant morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are relatively expensive compared to GV solution and ketoconazole has significant side effects especially in association with some of the treatments for HIV related problems. In children, either GV solutions or nystatin are used, GV is a fraction of the cost of nystatin. GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark them out as having HIV infections. A much more dilute solution of GV has proved equally effective in vitro and would not carry the same cosmetic problem. In this study of children, the investigators have compared the 3 solutions, 1% GV, 0.00165% GV and nystatin oral drops - all masked so that they look the same - to see if GV is more effective than nystatin, and to see if the weaker solution of GV is as effective as the stronger solution.
NCT00128323 ↗	A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis	Completed	University of Malawi College of Medicine	Phase 3	2002-11-01	In resource constrained societies and where HIV is a problem, oral thrush causes significant morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are relatively expensive compared to GV solution and ketoconazole has significant side effects especially in association with some of the treatments for HIV related problems. In children, either GV solutions or nystatin are used, GV is a fraction of the cost of nystatin. GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark them out as having HIV infections. A much more dilute solution of GV has proved equally effective in vitro and would not carry the same cosmetic problem. In this study of children, the investigators have compared the 3 solutions, 1% GV, 0.00165% GV and nystatin oral drops - all masked so that they look the same - to see if GV is more effective than nystatin, and to see if the weaker solution of GV is as effective as the stronger solution.
NCT00390780 ↗	Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients	Completed	Onxeo	Phase 3	2006-07-01	The purpose of this study is to evaluate the clinical cure of miconazole Lauriad 50 mg (1x50mg) Bioadhesive buccal tablets compared with clotrimazole troches (5x10mg) after 14 days of treatment (at the test of cure visit, at Day 17-19).
NCT00498680 ↗	Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i	Unknown status	Rambam Health Care Campus	Phase 4	2007-03-01	A prospective, randomized, 3-arm parallel trial on 45 males with ED that were never exposed to PDE5i therapy (naïve patients) will be enrolled.In each group, every patient will receive three treatment regimes (Viagra®50mg & Levitra®10mg, Viagra®100mg, Levitra®20mg), in different sequences of administration in such a manner that eventually each patient will receive all regimes in a double- blinded fasion.Safety will be evaluated at pre- screening by measuring hourly vital signs (blood pressure, heart rate)for 4 consecutive hours after taking half-dose combination. Any decrease in blood pressure of 20 mmhg below baseline will exclude the subject from the study. Effcacy will be evaluated by questionnaires (IIEF, Quality of erection questionnaire, grade of erection scale, Sear, QVS and Sexual Encounter Profiles for each sexual event). Non-parametric statistical analysis of the collected data Comparing the 3 groups will be performed.
NCT00668538 ↗	Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans	Completed	Odense University Hospital	N/A	2008-04-01	The purpose of this study, is to study the uptake of the pharmaceutical antifungal miconazole when used as a vaginal suppository in young women. The investigators want to know if the uptake is big enough to cause a biological effect (effect on CYP1A2 and CYP3A4 activity).
NCT00668538 ↗	Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans	Completed	University of Southern Denmark	N/A	2008-04-01	The purpose of this study, is to study the uptake of the pharmaceutical antifungal miconazole when used as a vaginal suppository in young women. The investigators want to know if the uptake is big enough to cause a biological effect (effect on CYP1A2 and CYP3A4 activity).

Clinical Trial Conditions for MICONAZOLE 3 COMBINATION PACK

Condition Name

Condition Name for MICONAZOLE 3 COMBINATION PACK
Intervention	Trials
Bacterial Vaginosis	3
Oral Lichen Planus	3
Otomycosis	3
Healthy	2

Condition MeSH

Condition MeSH for MICONAZOLE 3 COMBINATION PACK
Intervention	Trials
Candidiasis	6
Lichen Planus	3
Vaginosis, Bacterial	3
Candidiasis, Oral	3

Clinical Trial Locations for MICONAZOLE 3 COMBINATION PACK

Trials by Country

Trials by Country for MICONAZOLE 3 COMBINATION PACK
Location	Trials
United States	35
China	7
Brazil	5
Canada	4
Egypt	3

Trials by US State

Trials by US State for MICONAZOLE 3 COMBINATION PACK
Location	Trials
Florida	5
California	4
Alabama	3
Texas	3
North Carolina	2

Clinical Trial Progress for MICONAZOLE 3 COMBINATION PACK

Clinical Trial Phase

Clinical Trial Phase for MICONAZOLE 3 COMBINATION PACK
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
Phase 4	9

Clinical Trial Status

Clinical Trial Status for MICONAZOLE 3 COMBINATION PACK
Clinical Trial Phase	Trials
Completed	21
Recruiting	3
Not yet recruiting	3

Clinical Trial Sponsors for MICONAZOLE 3 COMBINATION PACK

Sponsor Name

Sponsor Name for MICONAZOLE 3 COMBINATION PACK
Sponsor	Trials
Hill Dermaceuticals, Inc.	3
Embil Pharmaceutical Co. Ltd	2
National Institute of Allergy and Infectious Diseases (NIAID)	2

Sponsor Type

Sponsor Type for MICONAZOLE 3 COMBINATION PACK
Sponsor	Trials
Other	29
Industry	15
NIH	3

Last updated: July 29, 2026

Miconazole 3 Combination Pack Clinical Trials Update, Market Analysis and Forecast (2024–2034)

What is the “Miconazole 3 Combination Pack” and which active ingredients does it contain?

Miconazole 3 combination pack products are typically marketed for vaginal mycotic infections using miconazole nitrate (or miconazole equivalent salt) delivered as a three-day vaginal regimen, often paired with a supporting external/adjunct component (commonly applicator devices and sometimes an additional antifungal or barrier-support component depending on market and pack configuration). Pack labeling and strength vary by country, and the term “Miconazole 3 Combination Pack” is used as a consumer-facing SKU descriptor rather than a single globally standardized formulation.

Common product pattern (typical industry construction):

• Active: miconazole (vaginal antifungal)
• Dose schedule: “3” implies three-day dosing
• Formulation format: intravaginal preparation with applicator or tube-and-applicator device
• “Combination pack” element: usually includes device + patient materials; in some markets it may include an additional complementary product unit

Clinical implication: these products are generally positioned for uncomplicated vulvovaginal candidiasis (VVC). Claims and endpoints in clinical trials usually map to mycological cure and symptom relief (itching, burning, discharge) within the treatment window and short follow-up.

What clinical trials and studies exist for miconazole 3-day vaginal regimens?

Published evidence for miconazole intravaginal therapy is extensive, but it is not always indexed under the exact consumer term “Miconazole 3 Combination Pack.” Trial datasets typically cluster around:

• 3-day miconazole regimens (intravaginal)
• comparative trials vs azoles (clotrimazole, tioconazole) and occasionally vs polyenes
• vehicle/aprator comparisons for intravaginal delivery

Trial design patterns (what endpoints are usually reported):

• Primary endpoints: clinical cure and mycological eradication at end of therapy and/or post-therapy assessment
• Secondary endpoints: time to symptom improvement, recurrence within short window, tolerability, local irritation

Regulatory lens: for established antifungal drugs like miconazole, many “new pack” or “combination pack” SKUs rely on bioequivalence/bridging, comparative local performance, or comparative efficacy demonstrations depending on whether the formulation or device changes meaningfully.

Are there ongoing or newly reported trials specifically for “Miconazole 3 Combination Pack” in 2024–2026?

No definitive, globally consistent public clinical-trial record can be tied to the exact SKU descriptor “Miconazole 3 Combination Pack” without a canonical product identifier (brand name, strength, and country). The term is widely used across markets for product bundles, while trial registrations typically use the pharmaceutical substance (miconazole) and the formulation rather than the consumer pack label.

What can be concluded from how these products are treated:

• If the underlying drug product is unchanged (same active, strength, and dosage form), clinical development is commonly limited to regulatory comparability rather than new phase III efficacy trials.
• If the pack includes a new delivery device or formulation variant, development may include localized performance studies rather than full outcomes trials.

Because the prompt requests a trials update with market and projection, this response focuses on the highest-confidence, drug-class reality: miconazole vaginal antifungals are mature, with development cycles now driven by labeling updates, device/pack changes, regulatory renewals, and market access tactics rather than large-scale late-stage trials.

Which patents protect miconazole 3-day vaginal antifungal packs?

For mature actives like miconazole, core substance patents are largely expired in most major jurisdictions. Current IP coverage usually sits in:

• formulation-specific patents (if any new excipients, polymorph, or device integrations exist)
• device patents (applicator design, delivery mechanics)
• method-of-use or new clinical claims (less common for established VVC treatment where label is established)

Given the lack of a single canonical, SKU-linked patent universe in the prompt, the only high-confidence statement is:

• Patent estate impact is usually local and formulation/device dependent, not driven by an enduring global “miconazole” monopoly.

How does the exclusivity timeline work for miconazole vaginal antifungals in major markets?

For established intravaginal antifungals:

• Composition-of-matter exclusivity is typically not the driver for current market differences.
• The main time-bound barriers in later years are usually regulatory data exclusivity/market exclusivity (when applicable), device-led IP, and label-specific protections tied to specific product presentations.

In practice, once formulation-level and labeling-level protections lapse, competitive entry tends to occur via generic or authorized equivalents, unless the incumbent maintains advantage via brand, distribution, and device usability.

What is the Orange Book status of “Miconazole 3 Combination Pack” in the US?

The US FDA Orange Book lists products by active ingredient and dosage form. Since “Miconazole 3 Combination Pack” is not a single universally defined Orange Book listing name, a complete Orange Book status assessment requires the exact FDA product identifiers (active ingredient, strength, dosage form, NDA/ANDA). Under the constraints here, the only accurate business conclusion is:

• US market presence for miconazole vaginal antifungals is generally off-patent/authorized generic, meaning Orange Book protections are unlikely to be the limiting factor for entry unless a specific brand product still has active patents or exclusivities tied to a particular presentation.

Which companies sell miconazole vaginal antifungal regimens and how concentrated is competition?

Miconazole intravaginal products are marketed by multiple generics and brand holders depending on geography. Competitive structure typically looks like:

• Incumbent brand historically present where brand recognition remains strong
• Multiple authorized generic equivalents in most mature markets
• Parallel trade and retailer private labels in higher-retail-permeation geographies

Market share drivers:

• pack price and pharmacy/online placement
• device usability (applicator experience)
• perceived tolerability and recurrence management positioning
• rebate and channel access, not trial novelty

What is the market size and growth forecast for vaginal candidiasis antifungals (miconazole segment)?

This forecast is best grounded at the therapeutic class level because “Miconazole 3 Combination Pack” is a pack descriptor that maps to a broader vulvovaginal candidiasis (VVC) antifungal category.

Category-level demand drivers:

• VVC prevalence and recurrence patterns
• switch of non-prescription and pharmacy decision-making
• persistent demand for short-course intravaginal azoles (3-day and related regimens)
• growing e-commerce share and retailer bundling tactics

Category-level headwinds:

• household access to alternative azoles and older antifungals
• clinician preference variability and guideline updates
• price compression from multi-source generics

Business projection logic for miconazole 3-day packs (high-confidence directional):

• Volume stability is likely due to chronic recurrence behavior.
• Revenue growth is typically modest and driven by inflation and channel mix.
• Margin pressure is high due to generic competition, with advantage accruing to firms that lower COGS and maintain device/pack conversion rates.

How should investors and R&D teams model revenue for a “miconazole 3-day combination pack” product?

Use a pack-level P&L model with the following structure:

• Unit demand: tied to VVC episode incidence and retailer turnover
• ASP trend: typically declining or flat in multi-generic markets, with occasional price support during supply disruptions
• COGS trend: driven by bulk API cost, formulation excipients, and applicator manufacturing
• Channel mix: e-commerce often increases unit volume at lower net price
• Marketing spend: usually maintenance-level unless re-launching a new device or label

Scenario framing (typical for off-patent OTC-prescription-overlap products):

• Base: flat volume, modest net price erosion
• Upside: stronger than average conversion through bundle offers and device improvements
• Downside: aggressive retailer private label and margin compression

What generic entry risks exist for miconazole 3-day vaginal packs?

For mature intravaginal azoles:

• Generic entry is usually feasible unless the incumbent retains active protections tied to formulation or delivery device.
• Regulatory barriers are usually modest: for equivalent generic presentations, approval tends to rely on pharmaceutical equivalence and, where required, bridging/bioperformance evidence.

The largest real-world risks for incumbents are:

• retailer switching to lower-cost equivalents/private label
• supply chain fragmentation in applicator/device components
• reduced brand differentiation as generics standardize

What formulation or device changes could create new IP barriers (and why they matter)?

Where “combination pack” materially changes the product, IP can reappear around:

• applicator mechanism (dose uniformity, reduced leakage, improved placement)
• viscosity modifiers and release kinetics
• packaging that improves patient adherence or reduces contamination risk

These are typically more actionable than classic composition-of-matter for miconazole since most core chemistry is mature and generic-ready.

How does “miconazole 3-day” compare with other OTC intravaginal azoles (clotrimazole, tioconazole) in real market terms?

Competitive comparison usually resolves to:

• course length and convenience
• tolerability profile (local irritation frequency)
• perceived efficacy in symptom resolution, even if mycological cure rates are similar across azoles
• pack usability (applicator design drives adherence)

Business impact: if a competitor’s pack reduces perceived hassle (simpler applicator, less mess, better instructions), it can gain shelf share even when clinical differentiation is limited.

What litigation and settlement dynamics affect miconazole pack competition?

For broadly genericized antifungals, major litigation is less common than for novel molecules, but disputes can arise when:

• a firm launches a presentation with device or packaging features that allegedly infringe a patent
• a brand asserts patents related to improved delivery or specific formulations

Absent a single SKU-linked patent ledger in the prompt, the actionable conclusion is:

• litigation impact is typically presentation-specific and localized, not systemic across all miconazole products.

Key Takeaways

• “Miconazole 3 Combination Pack” is a pack descriptor; clinical development and IP protections are generally formulation and device dependent, not driven by enduring global miconazole composition patents.
• For miconazole vaginal antifungals, the market is mature and multi-source, so competition is primarily driven by price, channel access, and pack/device usability rather than novel efficacy differentiation.
• Revenue growth for these off-patent/near-off-patent products is usually modest, with risk skewed toward price compression and private label substitution.
• Modeling should focus on unit volume stability, ASP erosion, applicator/device COGS, and channel mix, with upside tied to conversion improvements from bundle and device execution.

FAQs

1. Is miconazole 3-day vaginal therapy effective for recurrent vulvovaginal candidiasis?
2. Do miconazole combination packs include additional active ingredients or only packaging devices?
3. What are common reasons for treatment failure with intravaginal azoles like miconazole?
4. How do applicator/device differences influence adherence in 3-day intravaginal regimens?
5. What factors most influence OTC-to-pharmacy conversion for vaginal antifungal bundles?

References

1. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. FDA. Labeling and approval resources for intravaginal antifungal products (miconazole and related azoles). FDA.